Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANI Guidance Raise Can’t Stop Stock Price Slump

Another Strong Quarter For ANI Was Overshadowed By Panic Among Investors

Executive Summary

Stock prices at ANI Pharmaceuticals dropped 14.8% following its Q3 results announcement, despite a guidance raise from the company, after it noted that competitor supply disruptions seemed to be easing off.

You may also be interested in...



Impressive Q2 Performance Drives Further Guidance Raise At ANI

Management at ANI has upped its estimates for the second time this year after another impressive quarter, driven by Cortrophin gel and a strong generics performance.

ANI Revises Its Expectations Up Following Record Revenues

ANI has revised up its annual expectations in the face of an outstanding first quarter, which saw it beat market expectations by a substantial margin.

ANI Delivers On Cortrophin Gel US Launch

ANI Pharmaceuticals has finally delivered its long-awaited launch of purified Cortrophin Gel (repository corticotropin injection) in the US, accompanying the launch with its ‘Cortrophin In Your Corner’ dedicated program to increase access and provide reimbursement support.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153123

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel